AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) - Research analysts at Bloom Burton issued their Q1 2025 earnings estimates for shares of AbCellera Biologics in a research report issued on Monday, March 3rd. Bloom Burton analyst D. Martin anticipates that the company will earn ($0.19) per share for the quarter. The consensus estimate for AbCellera Biologics' current full-year earnings is ($0.59) per share. Bloom Burton also issued estimates for AbCellera Biologics' Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.17) EPS and FY2027 earnings at ($0.80) EPS.
Several other brokerages have also recently commented on ABCL. Stifel Nicolaus lowered their target price on shares of AbCellera Biologics from $12.00 to $10.00 and set a "buy" rating on the stock in a report on Friday, February 28th. Benchmark reaffirmed a "hold" rating on shares of AbCellera Biologics in a report on Monday, March 3rd. Finally, KeyCorp lowered their target price on shares of AbCellera Biologics from $5.00 to $4.00 and set an "overweight" rating on the stock in a report on Wednesday, January 8th.
Get Our Latest Stock Analysis on ABCL
AbCellera Biologics Price Performance
AbCellera Biologics stock traded down $0.05 during trading hours on Wednesday, hitting $2.33. The company had a trading volume of 4,301,434 shares, compared to its average volume of 2,267,487. The firm has a market cap of $694.31 million, a PE ratio of -3.82 and a beta of 0.45. AbCellera Biologics has a one year low of $2.20 and a one year high of $5.04. The firm has a 50-day moving average of $3.04 and a 200 day moving average of $2.83.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in ABCL. DKM Wealth Management Inc. acquired a new stake in shares of AbCellera Biologics during the 4th quarter worth approximately $29,000. State of New Jersey Common Pension Fund D acquired a new stake in shares of AbCellera Biologics during the 4th quarter worth approximately $36,000. Balyasny Asset Management L.P. acquired a new stake in shares of AbCellera Biologics during the 4th quarter worth approximately $40,000. Mariner LLC acquired a new stake in shares of AbCellera Biologics during the 4th quarter worth approximately $42,000. Finally, Boothbay Fund Management LLC acquired a new stake in shares of AbCellera Biologics during the 4th quarter worth approximately $46,000. 61.42% of the stock is owned by institutional investors.
AbCellera Biologics Company Profile
(
Get Free Report)
AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.
See Also
Before you consider AbCellera Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbCellera Biologics wasn't on the list.
While AbCellera Biologics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
